Laurus Labs Limited (LAURUSLABS)
Investor Presentation
Investor Presentation - Q2 & H1 FY27
- H1 FY27 revenue ₹4,233 Cr +31% y-y; EBITDA ₹1,406 Cr +72%, margin 33.2% +780 bps
- CDMO revenue up 71%, Affordable Medicines +13% in H1 FY27
- Q2 FY27 revenue ₹2,206 Cr +33% y-y; EBITDA ₹762 Cr +78%, margin 34.5% +850 bps
- Announced acquisitions to expand CDMO in Oligonucleotides and peptide-resins
- Capex ₹864 Cr (20% of revenue) for manufacturing and capability expansion
- Advanced biologics facility commissioning on track by end 2027
- Net debt to EBITDA improved to 1.0x; ROCE at 22.5%
- Strong ESG progress with SBTi targets and renewable energy investments
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 LAURUSLABS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add LAURUSLABS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Laurus Labs Limited
Important.
The summary above is generated automatically from Laurus Labs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.